Press Releases BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 21/01/2026 GMT			5-day change	1st Jan Change
56.77 ^USD	+0.82%		+2.84%	-4.48%

02:08pm	When America Starts to Feel Like a Risky Asset
01-20	Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy From Hold, Adjusts Price Target to $98 From $84	MT

Press Releases

01-12	BioMarin Appoints Arpit Davé Chief Digital and Information Officer	PR
01-08	BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA	PR
01-08	Veeva and BioMarin Form Long-Term Strategic Partnership	PR
12-19	BioMarin Pharmaceutical : Business Update	PU
11-11	BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England	PR
29/10/25	FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria	PR
27/10/25	BioMarin: Q3 Earnings Snapshot	AQ
27/10/25	BioMarin Pharmaceutical : Third Quarter 2025 Presentation	PU
27/10/25	BioMarin Pharmaceutical : Third Quarter 2025 Presentation	PU
27/10/25	BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update	PR
22/10/25	BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET	PR
08/09/25	BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting	PR
06/09/25	BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism	PR
27/08/25	BioMarin to Participate in Upcoming Investor Conferences	PR
04/08/25	BioMarin Pharmaceutical : Second Quarter 2025 Presentation	PU
04/08/25	BioMarin: Q2 Earnings Snapshot	AQ
04/08/25	BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS	PR
01/08/25	BioMarin Announces Appointment of Ian T. Clark to Board of Directors	PR
22/07/25	BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET	PR
25/06/25	BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN at International Society on Thrombosis and Haemostasis 2025 Congress	AQ
24/06/25	BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress	PR
12/05/25	BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings	PR
01/05/25	BioMarin: Q1 Earnings Snapshot	AQ
17/04/25	BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET	PR
02/04/25	BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Pharmaceuticals

Press Releases

Filters